These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 37114441)

  • 21. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV‑2 Mpro).
    Azevedo PHRA; Camargo PG; Constant LEC; Costa SDS; Silva CS; Rosa AS; Souza DDC; Tucci AR; Ferreira VNS; Oliveira TKF; Borba NRR; Rodrigues CR; Albuquerque MG; Dias LRS; Garrett R; Miranda MD; Allonso D; Lima CHDS; Muri EMF
    Sci Rep; 2024 Apr; 14(1):8991. PubMed ID: 38637583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a "Cocktail" of Potential SARS-COV-2 Main Protease Inhibitors through Virtual Screening of Known Chemical Components of Vitex negundo L. ("Lagundi").
    Cayona R; Creencia E
    Med Chem; 2022; 18(3):364-381. PubMed ID: 34148541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depicting the inhibitory potential of polyphenols from
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors.
    Khorsandi Z; Afshinpour M; Molaei F; Askandar RH; Keshavarzipour F; Abbasi M; Sadeghi-Aliabadi H
    J Biomol Struct Dyn; 2022 Oct; 40(17):7940-7948. PubMed ID: 33784944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular docking and simulation studies of natural compounds of
    Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
    J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating the promising SARS-CoV-2 main protease inhibitory activity of secoiridoids isolated from
    Al-Karmalawy AA; Alnajjar R; Elmaaty AA; Binjubair FA; Al-Rashood ST; Mansour BS; Elkamhawy A; Eldehna WM; Mansour KA
    J Biomol Struct Dyn; 2024 Aug; 42(13):6941-6953. PubMed ID: 37505066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
    Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
    J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation.
    Guo S; Xie H; Lei Y; Liu B; Zhang L; Xu Y; Zuo Z
    Bioorg Chem; 2021 May; 110():104767. PubMed ID: 33667900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease.
    Mótyán JA; Mahdi M; Hoffka G; Tőzsér J
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel
    Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of terpenoids as potential inhibitors of SARS-CoV-2 (main protease) and spike (RBD) via computer-aided drug design.
    Hadni H; Fitri A; Touimi Benjelloun A; Benzakour M; Mcharfi M; Benbrahim M
    J Biomol Struct Dyn; 2024 Sep; 42(15):8145-8158. PubMed ID: 37548619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
    Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
    J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease.
    Cheng AJT; Macalino SJY; Billones JB; Balolong MP; Murao LAE; Carrillo MCO
    J Mol Model; 2022 Oct; 28(11):345. PubMed ID: 36205801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress of SARS-CoV-2 Main protease peptide-like inhibitors.
    Liu X; Ren X; Hua M; Liu F; Ren X; Sui C; Li Q; Luo F; Jiang Z; Xia Z; Chen J; Yang B
    Chem Biol Drug Des; 2024 Jan; 103(1):e14425. PubMed ID: 38082476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.